复方苦参注射液联合NP方案治疗晚期非小细胞肺癌63例临床观察

Clinical observation on healing 63 case advanced stage NSCLC with composite kusheng injection and NP program

目的:观察复方苦参注射液联合NP方案治疗晚期非小细胞肺癌的临床疗效。方法:63例晚期非小细胞肺癌患者随机分为治疗组32例和对照组31例。治疗组采用复方苦参注射液20ml静脉滴注,每天静点1次,连用6周,同时给予NP方案化疗(盖诺25mg/m2,静脉点滴,第1、8天,顺铂20mg/m2,静脉点滴,第1～4天),对照组单用NP方案化疗。两组疗程均为2周期。观察两组治疗后近期疗效、疼痛缓解、KPS评分改善、细胞免疫和毒副反应情况。结果:治疗组与对照组在KPS评分改善、疼痛缓解具有统计学意义(P<0.05);治疗组近期总有效率为62.5%,对照组为48.4%(P>0.05);不良反应发生率两组近似,但治疗组不良反应症状普遍较轻;细胞免疫:治疗组T淋巴细胞中T4及T4/T8比值显著高于对照组(P<0.05)。结论:复方苦参注射液治疗晚期非小细胞肺癌能明显缓解疼痛,提高KPS评分,减少化疗毒副反应,提高患者对化疗的耐受能力,改善生存质量。

Objective： To compare the therapeutic effect of composite kusheng injection combined with NP program healing advanced stage of non-small cell lung cancer （NSCLC） . Methods： Sixty-three cases of advanced stage NSCLC patients were devided into therapy group and control group on random. The therapy groups were gived kusheng injection intervenous drop infusion once every day and it lasted 6 weeks, meanwhile chemotherapy with NP program （NVB 25 mg/m^2, iv, dl, 8; DDP 20 mg/m^2 iv, d1-4）. The control group were gived chemotherapy of NP program only. Both the period of treatment is 2 weeks. We observed therapeutic effect after therapy, easement of pain, KPS score improvement, cytoimmunity and side effect. Results： The aspects of KPS score improvement, easement of pain have statistical significance （P 0.05）. Treatment group total effective rate is 62.5%, and that of control group is 48.4% （P）0.05）. Side effect incidence rate is smiliar between those two groups, but side effect of the therapy group is generally light . T4 and T4/T8 of the therapy group are higher than that of control group （P 〈0.05）. Conclusion： Our preliminary results suggest that therapy advanced stage NSCLC with composite kusheng injection could relieve pain, reinforce KPS score, relieve side effect, enhance chemotherapy tolerance of paticorts and improve life quality.